Industry News
Pharmaceutical Industry News
Real-world data has become table…
Real-world data has become table stakes. The next challenge is connecting it to genetic insight that can sharpen R&D decisions.
Lonza’s plans for a new…
Lonza's plans for a new spray-drying facility in Bend, Oregon, affirm the company's commitment both to high-margin medicines and the U.S. At the same time, fellow Swiss CDMO CordenPharma is also making expansion moves, albeit
With positive phase 3 results in…
With positive phase 3 results in hand, AbbVie is one step closer to expanding the reach of its key migraine preventative Qulipta, also known as atogepant.
In a move that at least one local…
In a move that at least one local HIV charity has deemed “profoundly disappointing,” England's health technology assessor NICE is currently recommending against coverage of Gilead Sciences’ landmark twice-a-year PrEP medication lenacapavir on the National
Novartis’ recent dual clinical…
Novartis’ recent dual clinical setbacks have prompted questions from a major shareholder about the board’s oversight of dealmaking.
As Samsung Biologics works to…
As Samsung Biologics works to close a massive buyout to branch out into peptides, the Korean CDMO’s bread-and-butter contracting work continues to gin up big-ticket contracts from the drug industry.
A New Drug Lifts the Fog of Sleepiness for Those With Narcolepsy
The first-of-its-kind drug offers a reprieve for people who live with the debilitating sleep disorder.
The “Serve Up Protection”…
The "Serve Up Protection" Nuvaxovid education campaign will take place on and off the court, Sanofi said.
WuXi AppTec’s Ke Chen discusses…
WuXi AppTec’s Ke Chen discusses trends reshaping API manufacturing – while diligence, understanding and controlling the process remains the cornerstone
Akeso and Summit’s ivonescimab…
Akeso and Summit’s ivonescimab reduced the risk of death by 27% compared with Keytruda in the phase 3 Harmoni-2 trial in first-line, PD-L1-positive non-small cell lung cancer, with particularly strong data in the PD-L1-high group.
Bayer has won first-line approval…
Bayer has won first-line approval for its tyrosine kinase inhibitor, Hyrnuo, in patients with HER2-mutant non-small cell lung cancer. The green light comes around half a year after a similar nod for rival TKI med
The 60-second ad sees…
The 60-second ad sees "Yellowstone" actor Kevin Costner doing the math on the benefits of early cancer detection with Caris' Caris Detect blood test.
With a phase 3 win now fleshed out…
With a phase 3 win now fleshed out and an FDA filing recently submitted, BioMarin is advancing expansion plans for Voxzogo, looking to extend the dwarfism drug’s reach as it faces new pressure in its
Merck continues sweeping staff…
Merck continues sweeping staff reductions, laying off 54 at its Rahway headquarters. The staff changes are set to take effect in December and January.
As drug discovery is…
As drug discovery is revolutionized by AI, the machinery built to get life-saving medicines to market remains trapped in a different era. Here’s how we solve that.
In a stabilizing move, the…
In a stabilizing move, the Department of Health and Human Services announced Tuesday afternoon that it has tapped Michael Davis, M.D., Ph.D., and Karim Mikhail—who’ve been serving as acting directors of CDER and CBER, respectively—to
RFK Jr. Promised Children’s Health Reforms. Here’s How He Did.
A year after the Trump administration laid out its plan to improve the health of American children, we examine where those efforts stand.
Exclusive insights from the…
Exclusive insights from the Patients as Partners Advisory Board on the biggest challenges and opportunities shaping patient engagement, patient advocacy, clinical trial participation, trust, transparency, and patient-focused drug development.
Spying a “golden decade”…
Spying a “golden decade” beyond the branded drug industry’s looming patent cliff, Sandoz is making big bets on its biosimilar capabilities in the coming years.
While Amgen gave no numerical…
While Amgen gave no numerical results from Imdelltra's latest overall survival win in first-line small cell lung cancer, R&D chief Jay Bradner said data suggest the DLL3 bispecific “will further revolutionize the standard for survival